The DOI matches its Crossref record.
Evidence Report: The efficacy and safety of mitoxantrone (Novantrone) in the treatment of multiple sclerosis [RETIRED]: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology
Open accessAbstract
OBJECTIVE: The chemotherapeutic agent mitoxantrone was approved for use in multiple sclerosis (MS) in 2000. After a review of all the available evidence, the original report of the Therapeutics and Technology Assessment Subcommittee in 2003 concluded that mitoxantrone probably reduced clinical attack rates, MRI activity, and disease progression. Subsequent reports of decreased systolic function, heart failure, and leukemia prompted the US Food and Drug Administration to institute a "black box" warning in 2005. This review was undertaken to examine the available literature on the efficacy and safety of mitoxantrone use in patients with MS since the initial report. METHODS: Relevant articles were obtained through a review of the medical literature and the strength of the available evidence was graded according to the American Academy of Neurology evidence classification scheme. RESULTS: The accumulated Class III and IV evidence suggests an increased incidence of systolic dysfunction and therapy-related acute leukemia (TRAL) with mitoxantrone therapy. Systolic dysfunction occurs in approximately 12% of patients with MS treated with mitoxantrone, congestive heart failure occurs in approximately 0.4%, and leukemia occurs in approximately 0.8%. The number needed to harm is 8 for systolic dysfunction and 123 for TRAL. There is no new efficacy evidence that would change the recommendation from the previous report. CONCLUSIONS: The risk of systolic dysfunction and leukemia in patients treated with mitoxantrone is higher than suggested at the time of the previous report, although comprehensive postmarketing surveillance data are lacking.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Multiple Sclerosis: Current and Emerging Disease-Modifying Therapies and Treatment Strategies
Wingerchuk, D. M., & Carter, J. L. (2014) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2013.11.002 · Cited by 416
(PDWP), O. B. O. T. E. A. D. W. P. (. A. P. D. W. P., Snowden, J. A., Saccardi, R., Allez, M., Ardizzone, S., Arnold, R., Cervera, R., Denton, C., Hawkey, C., Labopin, M., et al. (2012) · Bone Marrow Transplantation · doi:10.1038/bmt.2011.185 · Cited by 328
Disease-modifying therapies and infectious risks in multiple sclerosis
Winkelmann, A., Loebermann, M., Reisinger, E. C., Hartung, H.-P., & Zettl, U. K. (2016) · Nature Reviews Neurology · doi:10.1038/nrneurol.2016.21 · Cited by 254
Clinical features of MS associated with Leber hereditary optic neuropathy mtDNA mutations
Pfeffer, G., Burke, A., Yu-Wai-Man, P., Compston, D. A. S., & Chinnery, P. F. (2013) · Neurology · doi:10.1212/01.wnl.0000437308.22603.43 · Cited by 122
Sex-dependent treatment of chronic EAE with partial MHC class II constructs
Benedek, G., Chaudhary, P., Meza-Romero, R., Calkins, E., Kent, G., Offner, H., Bourdette, D., & Vandenbark, A. A. (2017) · Journal of Neuroinflammation · doi:10.1186/s12974-017-0873-y · Cited by 13
Metadata
- Authors
- Marriott, J. J., Miyasaki, J. M., Gronseth, G., & O'Connor, P. W.
- Venue
- Neurology
- Published
- 2010-05-04
- Volume
- 74
- Issue
- 18
- Pages
- 1463-1470
- ISSN
- 0028-3878 (ISSN-L)
- 1526-632X
- OpenAlex
- W2165059791
- Cited by
- 233
- References
- 0
- FWCI
- 21.35
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Evidence Report: The efficacy and safety of mitoxantrone (Novantrone) in the treatment of multiple sclerosis [RETIRED]: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. https://app.cochat.ai/papers/10.1212/wnl.0b013e3181dc1ae0
- The paper
- Marriott, J. J., Miyasaki, J. M., Gronseth, G., & O'Connor, P. W. (2010). Evidence Report: The efficacy and safety of mitoxantrone (Novantrone) in the treatment of multiple sclerosis [RETIRED]: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology. https://doi.org/10.1212/wnl.0b013e3181dc1ae0
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.